WHO ICTRP trial
Phase I/II study for patients with newly diagnosed glioblastoma testing…
NL-OMON32210 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON32210 |
|---|---|
| Public title | Phase I/II study for patients with newly diagnosed glioblastoma testing nelfinavir in combination with concomitant temozolomide and radiotherapy. |
| Scientific title | Phase I/II study for patients with newly diagnosed glioblastoma testing nelfinavir in combination with concomitant temozolomide and radiotherapy. - Phase I/II study with nelfinavir and radiochemotherapy for glioblastoma |
| Primary sponsor | Academisch Ziekenhuis Maastricht |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Countries | The Netherlands |
| Conditions | glioblastoma;10029211;glioblastoma |
| Interventions | Treatment with Nelfinavir ;glioblastoma;Nelfinavir;radiotherapy;Temozolomide |
| Registration date | Oct 21, 2008 |
| Target size | 58 |
| Secondary IDs | 2008-001078-34;NCT00694837;NL22167.068.08 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: